{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:03:56Z","timestamp":1758845036531,"version":"3.44.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.ygyno.2012.12.009","type":"journal-article","created":{"date-parts":[[2012,12,16]],"date-time":"2012-12-16T10:45:52Z","timestamp":1355654752000},"page":"488-492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Low-grade and high-grade serous Mullerian carcinoma: Review and analysis of publicly available gene expression profiles"],"prefix":"10.1016","volume":"128","author":[{"given":"Taymaa","family":"May","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melina","family":"Shoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher P.","family":"Crum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wa","family":"Xian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinod","family":"Vathipadiekal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Birrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Tone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. Joan","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ygyno.2012.12.009_bb0005","first-page":"69","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ygyno.2012.12.009_bb0010","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1146\/annurev.pathol.4.110807.092246","article-title":"Ovarian cancer","volume":"4","author":"Cho","year":"2009","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"10.1016\/j.ygyno.2012.12.009_bb0015","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1200\/JCO.2006.07.9970","article-title":"Early events in the pathogenesis of epithelial ovarian cancer","volume":"26","author":"Landen","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.12.009_bb0020","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0002-9440(10)63708-X","article-title":"Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis","volume":"164","author":"Shih","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ygyno.2012.12.009_bb0025","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc2644","article-title":"The biology of ovarian cancer: new opportunities for translation","volume":"9","author":"Bast","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ygyno.2012.12.009_bb0030","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00004347-198906000-00008","article-title":"A new histologic grading index in ovarian carcinoma","volume":"8","author":"Bichel","year":"1989","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ygyno.2012.12.009_bb0035","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1006\/gyno.1998.5051","article-title":"Toward the development of a universal grading system for ovarian epithelial carcinoma. Prognostic significance of histopathologic features\u2014Problems involved in the architectural grading system","volume":"70","author":"Shimizu","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.12.009_bb0040","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/00004347-200001000-00003","article-title":"Histopathologic grading of ovarian carcinoma: a review and proposal","volume":"19","author":"Silverberg","year":"2000","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ygyno.2012.12.009_bb0045","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00000478-200404000-00009","article-title":"Grading ovarian serous carcinoma using a two-tier system","volume":"28","author":"Malpica","year":"2004","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"10.1016\/j.ygyno.2012.12.009_bb0050","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1097\/PAS.0b013e31803199b0","article-title":"Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma","volume":"31","author":"Malpica","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.ygyno.2012.12.009_bb0055","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.ygyno.2006.05.030","article-title":"Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum","volume":"103","author":"Seidman","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ygyno.2012.12.009_bb0060","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0002-9440(10)62549-7","article-title":"Diverse tumorigenic pathways in ovarian serous carcinoma","volume":"160","author":"Singer","year":"2002","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.ygyno.2012.12.009_bb0065","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ygyno.2010.01.006","article-title":"Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary","volume":"117","author":"May","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.12.009_bb0070","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/S0140-6736(01)05992-X","article-title":"Tubal ligation and risk of ovarian cancer","volume":"358","author":"Piek","year":"2001","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ygyno.2012.12.009_bb0075","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/GCO.0b013e328011a21f","article-title":"The distal fallopian tube: a new model for pelvic serous carcinogenesis","volume":"19","author":"Crum","year":"2007","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"13","key":"10.1016\/j.ygyno.2012.12.009_bb0080","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1158\/1078-0432.CCR-07-4959","article-title":"Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma","volume":"14","author":"Tone","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.ygyno.2012.12.009_bb0085","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/modpathol.2009.89","article-title":"Candidate serous cancer precursors in fallopian tube epithelium of BRCA1\/2 mutation carriers","volume":"22","author":"Shaw","year":"2009","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ygyno.2012.12.009_bb0090","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1097\/01.pas.0000166367.68459.7d","article-title":"An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2\/neu, and C-KIT in high-grade neoplasms","volume":"29","author":"O'Neill","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ygyno.2012.12.009_bb0095","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1525-1438.2007.00864.x","article-title":"Ovarian tumors of borderline malignancy: a review of 247 patients from 1991 to 2004","volume":"17","author":"Wong","year":"2007","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2012.12.009_bb0100","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/jnci\/95.6.484","article-title":"Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma","volume":"95","author":"Singer","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2012.12.009_bb0105","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/01.pas.0000146025.91953.8d","article-title":"Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation","volume":"29","author":"Singer","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ygyno.2012.12.009_bb0110","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/01.pgp.0000130446.84670.93","article-title":"Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data","volume":"23","author":"Gilks","year":"2004","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ygyno.2012.12.009_bb0115","doi-asserted-by":"crossref","first-page":"6432","DOI":"10.1158\/1078-0432.CCR-04-0893","article-title":"Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas","volume":"10","author":"Hsu","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2012.12.009_bb0120","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00004347-200301000-00009","article-title":"Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor)","volume":"22","author":"Singer","year":"2003","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ygyno.2012.12.009_bb0125","doi-asserted-by":"crossref","first-page":"10602","DOI":"10.1158\/0008-5472.CAN-05-2240","article-title":"Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary","volume":"65","author":"Bonome","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2012.12.009_bb0130","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/mc.10098","article-title":"Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma","volume":"36","author":"Jazaeri","year":"2003","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.ygyno.2012.12.009_bb0135","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/sj.onc.1208298","article-title":"Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential","volume":"24","author":"Meinhold-Heerlein","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.ygyno.2012.12.009_bb0310","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0020-7292(03)90118-4","article-title":"Carcinoma of the ovary. 25th annual report on the results of treatment of gynecological cancer","volume":"83","author":"Heintz","year":"2003","journal-title":"Int J Gynecol Obstet"},{"issue":"1","key":"10.1016\/j.ygyno.2012.12.009_bb0145","first-page":"S5","article-title":"Recurrent low grade serous carcinoma of the ovary is relatively chemoresistant","volume":"108","author":"Gershenson","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2012.12.009_bb0315","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ajog.2008.04.031","article-title":"Utilization of a uniform grading system for interpreting serous ovarian cancer","volume":"199","author":"Lachance","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2012.12.009_bb0155","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ygyno.2007.11.013","article-title":"Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum","volume":"108","author":"Schmeler","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.ygyno.2012.12.009_bb0160","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11912-008-0078-8","article-title":"Low-grade serous ovarian cancer: a unique disease","volume":"10","author":"Schmeler","year":"2008","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"10.1016\/j.ygyno.2012.12.009_bb0165","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/01.AOG.0000227787.24587.d1","article-title":"Clinical behavior of stage II\u2013IV low-grade serous carcinoma of the ovary","volume":"108","author":"Gershenson","year":"2006","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2012.12.009_bb0170","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1006\/gyno.2002.6736","article-title":"Micropapillary serous ovarian carcinoma: surgical management and clinical outcome","volume":"86","author":"Bristow","year":"2002","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2012.12.009_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ygyno.2012.12.009_bb0320","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/IGC.0b013e31821b2568","article-title":"2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the fourth ovarian cancer consensus conference","volume":"21","author":"Stuart","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"Suppl. 8","key":"10.1016\/j.ygyno.2012.12.009_bb0325","doi-asserted-by":"crossref","first-page":"viii13","DOI":"10.1093\/annonc\/mdi962","article-title":"Gynecologic Cancer Intergroup; GOG; NCIC-CTG; AGO-OVAR; ANZGOG; JGOG; GINECO; SGCTG, MRC\/NCRI, NSGO, RTOG, GEICO; EORTC. Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens","volume":"16","author":"Thigpen","year":"2005","journal-title":"Ann Oncol"},{"issue":"S1","key":"10.1016\/j.ygyno.2012.12.009_bb0330","article-title":"Carcinoma of the ovary. 26th annual report on the results of treatment in gynecological cancer","volume":"95","author":"Heintz","year":"2006","journal-title":"Int J Gynecol Obstet"},{"issue":"8","key":"10.1016\/j.ygyno.2012.12.009_bb0195","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1097\/01.pas.0000166367.68459.7d","article-title":"An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinoma: significantly higher expression of p53, MIB1, BCL2, HER-2\/Neu, and C-KIT in high-grade neoplasms","volume":"29","author":"O'Neill","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ygyno.2012.12.009_bb0200","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.ygyno.2012.12.009_bb0335","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1158\/1541-7786.MCR-08-0193","article-title":"Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors","volume":"6","author":"Anglesio","year":"2008","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.ygyno.2012.12.009_bb0210","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1755-8794-2-71","article-title":"Gene expression profiling supports the hypothesis that human ovarian surface epithelia are multipotent and capable of serving as ovarian cancer initiating cells","volume":"2","author":"Bowen","year":"2009","journal-title":"BMC Med Genomics"},{"issue":"6","key":"10.1016\/j.ygyno.2012.12.009_bb0215","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ccr.2009.10.018","article-title":"A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2","volume":"16","author":"Mok","year":"2009","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.ygyno.2012.12.009_bb0220","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/modpathol.2009.92","article-title":"PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas","volume":"22","author":"Tung","year":"2009","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.ygyno.2012.12.009_bb0225","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1158\/0008-5472.CAN-09-3833","article-title":"Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells","volume":"70","author":"Iorio","year":"2010","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.ygyno.2012.12.009_bb0230","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/biostatistics\/4.2.249","article-title":"Exploration, normalization, and summaries of high density oligonucleotide array probe level data","volume":"4","author":"Irizarry","year":"2003","journal-title":"Biostatistics"},{"issue":"1","key":"10.1016\/j.ygyno.2012.12.009_bb0235","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/biostatistics\/kxj037","article-title":"Adjusting batch effects in microarray expression data using empirical Bayes methods","volume":"8","author":"Johnson","year":"2007","journal-title":"Biostatistics"},{"issue":"5","key":"10.1016\/j.ygyno.2012.12.009_bb0240","first-page":"296","article-title":"The role of the fallopian tube in ovarian cancer","volume":"10","author":"Tone","year":"2012","journal-title":"Clin Adv Hematol Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2012.12.009_bb0245","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc1780","article-title":"KLF4, p21 and context-dependent opposing forces in cancer","volume":"6","author":"Rowland","year":"2006","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"10.1016\/j.ygyno.2012.12.009_bb0250","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1593\/neo.08604","article-title":"Clusterin interacts with Paclitaxel and confer Paclitaxel resistance in ovarian cancer","volume":"10","author":"Park","year":"2008","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/j.ygyno.2012.12.009_bb0340","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1124\/jpet.109.163949","article-title":"Cyclosporine up-regulates Kr\u00fcppel-like factor-4 (KLF4) in vascular smooth muscle cells and drives phenotypic modulation in vivo","volume":"333","author":"Garvey","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.ygyno.2012.12.009_bb0345","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1158\/1078-0432.CCR-1151-3","article-title":"Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma","volume":"10","author":"Apte","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.ygyno.2012.12.009_bb0265","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s00432-008-0408-0","article-title":"Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects","volume":"134","author":"Mundhenke","year":"2008","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2012.12.009_bb0270","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ygyno.2006.10.052","article-title":"AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate","volume":"105","author":"Shaw","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2012.12.009_bb0275","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.ygyno.2012.02.034","article-title":"Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube","volume":"125","author":"Noguera","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.12.009_bb0285","first-page":"144","article-title":"Long-term follow-up confirms a survival advantage of the paclitaxel\u2013cisplatin regimen over the cyclophosphamide\u2013cisplatin combination in advanced ovarian cancer","volume":"13","author":"Piccart","year":"2003","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2012.12.009_bb0290","first-page":"1311","article-title":"Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines","volume":"63","author":"Selvakumaran","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2012.12.009_bb0295","first-page":"5299","article-title":"Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer","volume":"9","author":"Reed","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2012.12.009_bb0300","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc1123","article-title":"Ovarian cancer: strategies for overcoming resistance to chemotherapy","volume":"3","author":"Agarwal","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ygyno.2012.12.009_bb0305","doi-asserted-by":"crossref","first-page":"5806","DOI":"10.1158\/0008-5472.CAN-11-0025","article-title":"Modulating microtubule stability enhances the cytotoxic response of cancer cells to paclitaxel","volume":"71","author":"Ahmed","year":"2011","journal-title":"Cancer Res"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825812009560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825812009560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:37:09Z","timestamp":1758771429000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825812009560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0090825812009560"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2012.12.009","relation":{},"ISSN":["0090-8258"],"issn-type":[{"type":"print","value":"0090-8258"}],"subject":[],"published":{"date-parts":[[2013,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-grade and high-grade serous Mullerian carcinoma: Review and analysis of publicly available gene expression profiles","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2012.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}